Approval · Notice of Compliance 22941 · 2019
RENFLEXIS: Notice of Compliance 22941
Issued November 22, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22941
- Date
- November 22, 2019
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing facility
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RENFLEXIS | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL